Glasser C, Chickering J, Wilson P, Florine E, Winrow C, Wright C. A Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and central nervous system activity of CY6463 when administered to participants with Alzheimer’s disease with vascular pathology. Alzheimer's & Dementia, 31 December 2021 Alzheimer's & Dementia
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.